23
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Radiation Dose‐Enhancement Is a Potent Radiotherapeutic Effect of Rare‐Earth Composite Nanoscintillators in Preclinical Models of Glioblastoma

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To improve the prognosis of glioblastoma, innovative radiotherapy regimens are required to augment the effect of tolerable radiation doses while sparing surrounding tissues. In this context, nanoscintillators are emerging radiotherapeutics that down‐convert X‐rays into photons with energies ranging from UV to near‐infrared. During radiotherapy, these scintillating properties amplify radiation‐induced damage by UV‐C emission or photodynamic effects. Additionally, nanoscintillators that contain high‐Z elements are likely to induce another, currently unexplored effect: radiation dose‐enhancement. This phenomenon stems from a higher photoelectric absorption of orthovoltage X‐rays by high‐Z elements compared to tissues, resulting in increased production of tissue‐damaging photo‐ and Auger electrons. In this study, Geant4 simulations reveal that rare‐earth composite LaF 3:Ce nanoscintillators effectively generate photo‐ and Auger‐electrons upon orthovoltage X‐rays. 3D spatially resolved X‐ray fluorescence microtomography shows that LaF 3:Ce highly concentrates in microtumors and enhances radiotherapy in an X‐ray energy‐dependent manner. In an aggressive syngeneic model of orthotopic glioblastoma, intracerebral injection of LaF 3:Ce is well tolerated and achieves complete tumor remission in 15% of the subjects receiving monochromatic synchrotron radiotherapy. This study provides unequivocal evidence for radiation dose‐enhancement by nanoscintillators, eliciting a prominent radiotherapeutic effect. Altogether, nanoscintillators have invaluable properties for enhancing the focal damage of radiotherapy in glioblastoma and other radioresistant cancers.

          Abstract

          Radiation dose‐enhancement induced by rare‐earth composite nanoscintillators is predicted by in silico simulations and unequivocally demonstrates in vitro in microtumor models of glioblastoma, using tunable monochromatic synchrotron radiation. Radiation dose‐enhancement ultimately elicitsa prominent radiotherapeutic effect in a syngeneic orthotopic model of aggressive glioblastoma. These results prove the strong ability of rare‐earth composite nanoscintillators to enhance the focal damage of radiotherapy.

          Related collections

          Most cited references1

          • Record: found
          • Abstract: not found
          • Article: not found

          Tables of X‐ray mass attenuation coefficients and mass energy‐absorption coefficients 1 keV to 20 MeV for elements Z = 1 to 92 and 48 additional substances of dosimetric interest

            Bookmark

            Author and article information

            Contributors
            Anne-laure.bulin@inserm.fr
            Helene.elleaume@inserm.fr
            Journal
            Adv Sci (Weinh)
            Adv Sci (Weinh)
            10.1002/(ISSN)2198-3844
            ADVS
            Advanced Science
            John Wiley and Sons Inc. (Hoboken )
            2198-3844
            07 September 2020
            October 2020
            : 7
            : 20 ( doiID: 10.1002/advs.v7.20 )
            : 2001675
            Affiliations
            [ 1 ] Synchrotron Radiation for Biomedical Research (STROBE) UA7 INSERM Université Grenoble Alpes Medical Beamline at the European Synchrotron Radiation Facility 71 Avenue des Martyrs Grenoble Cedex 9 38043 France
            [ 2 ] Université de Lyon École Normale Supérieure de Lyon CNRS UMR 5182 Université Claude Bernard Lyon 1 Laboratoire de Chimie Lyon F69342 France
            [ 3 ] Deutsches Elektronen‐Synchrotron DESY Notkestrasse 85 Hamburg DE‐22607 Germany
            [ 4 ] Cancer Targets and Experimental Therapeutics Institute for Advanced Biosciences Université Grenoble Alpes INSERM U1209 CNRS UMR5309 Allée des Alpes La Tronche 38700 France
            [ 5 ] Cancer Clinical Laboratory Grenoble University Hospital Grenoble 38700 France
            [ 6 ] Department Physik Universität Hamburg Luruper Chaussee 149 Hamburg 22761 Germany
            [ 7 ] Université Grenoble Alpes CEA CNRS IRIG SyMMES UMR 5819 Grenoble F‐38000 France
            [ 8 ] Institut Lumière Matière UMR5306 Université Claude Bernard Lyon 1 CNRS Villeurbanne Cedex 69622 France
            Author notes
            Author information
            https://orcid.org/0000-0002-2644-8626
            https://orcid.org/0000-0002-9516-5048
            https://orcid.org/0000-0001-8696-0499
            https://orcid.org/0000-0002-9425-1577
            https://orcid.org/0000-0002-7123-6358
            https://orcid.org/0000-0002-0205-9837
            https://orcid.org/0000-0001-6063-5532
            https://orcid.org/0000-0001-6355-7592
            https://orcid.org/0000-0002-0084-3775
            Article
            ADVS1949
            10.1002/advs.202001675
            7578894
            f86df683-edf0-4bcc-977b-c42ba6e98b94
            © 2020 The Authors. Published by Wiley‐VCH GmbH

            This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

            History
            : 07 May 2020
            : 16 June 2020
            Page count
            Figures: 8, Tables: 1, Pages: 18, Words: 13146
            Funding
            Funded by: Fondation pour la Recherche Médicale , open-funder-registry 10.13039/501100002915;
            Award ID: ARF20170938739
            Funded by: Région Auvergne Rhône‐Alpes
            Funded by: Ligue Contre le Cancer , open-funder-registry 10.13039/501100004099;
            Award ID: R19ELLEAUME
            Funded by: LABEX PRIMES
            Award ID: ANR‐11‐LABX‐0063
            Funded by: Université de Lyon , open-funder-registry 10.13039/501100011074;
            Award ID: ANR‐11‐ISEX‐0007
            Funded by: Rotary Club
            Award ID: I‐20181082 EC
            Award ID: 730872
            Funded by: ANR , open-funder-registry 10.13039/501100001665;
            Award ID: ANR‐11‐INBS‐0006
            Categories
            Full Paper
            Full Papers
            Custom metadata
            2.0
            October 21, 2020
            Converter:WILEY_ML3GV2_TO_JATSPMC version:5.9.3 mode:remove_FC converted:22.10.2020

            glioblastoma,nanoscintillators,radiation dose‐enhancement,synchrotron radiation,x‐ray‐induced photodynamic therapy

            Comments

            Comment on this article